Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE (UK National Institute for Clinical Excellence) confirms analogue-to-digital hearing technology shift:

This article was originally published in Clinica

Executive Summary

The UK's National Institute for Clinical Excellence (NICE) has withdrawn guidance encouraging the NHS to use analogue hearing aids pending the evaluation of digital technology. The move is confirmation of the increasing access to the latter. In July 2000, NICE had recommended that the NHS rely on analogue technology, "[making] full use of the available range of analogue aids", while remaining "more cautious" about their digital successors. The guidance recognised, however, the rapid evolution in hearing-aid technology and proposed waiting for the results of the NHS digital aid pilots, which at that time were being established. The guidance review, due in July 2002, was delayed in order to incorporate their results. NICE has confirmed that they were successful.

You may also be interested in...



What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

P&G: Sales Growth Strongest When Rising Tide Floats All Competitors Across All Categories

P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Topics

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel